Latest News
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
13 May 2024
NEW YORK, May 13, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it has submitted an FDA request to obtain Orphan...
MEDIA: Neurology Live Video Interview: Potential of Nasal Foralumab in Treating Non-Active Secondary Progressive MS: Tarun Singhal, MD, MBBS
29 April 2024
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
25 April 2024
NEW YORK, April 25, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced for the first time, quantitative data showing improvement in...
MEDIA: MS News Today: Foralumab found to ease fatigue in SPMS patients in access program
24 April 2024
Link to original article: Foralumab eases fatigue in most SPMS patients in access program (multiplesclerosisnewstoday.com)
Foralumab found to ease fatigue in SPMS patients in access program
Use of nasal spray reduced levels after...
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
23 April 2024
NEW YORK, April 23, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration (FDA) has...
MEDIA: Neurology Live: Nasal Foralumab Shows Attenuation of Microglial Activation, Clinical Stabilization in Non-Active Secondary Progressive MS With PIRA
22 April 2024
Nasal Foralumab Shows Attenuation of Microglial Activation, Clinical Stabilization in Non-Active Secondary Progressive MS With PIRA
Foralumab's anti-CD3 mechanism modulates T cell function, offering potential benefits for the challenging-to-treat na-SPMS patients.
Link to original article: Nasal Foralumab Shows Attenuation of Microglial Activation,...
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
22 April 2024
- 70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months of Follow-up
- All...
MEDIA: Neurology Today: Anti-CD3 Antibody Foralumab Shows Promise in PIRA, Measured by Novel PET Ligand
19 April 2024
Link to original article: Neurology Today (lww.com)
Anti-CD3 Antibody Foralumab Shows Promise in PIRA, Measured by Novel PET Ligand
By Gina Shaw
April 4, 2024
The fully human anti-CD3 antibody foralumab attenuates microglial activation in patients with non-active secondary progressive multiple...
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
19 April 2024
- - Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) -
- - Data presented in a platform...
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
18 April 2024
- - Oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (MS) patients with PIRA as measured by changes in PET scans -
NEW YORK, April 18, 2024 –...